Two dose regimens of Aes-103 given for 28 days in stable sickle cell disease
Sickle Cell Disease
Enrolment: 35 · Results not recorded
Loading the evidence…
Device · Composite device: PVA/sodium alginate hydrogel carrying 5-hydroxymethylfurfural (5-HMF) plus silver nanoparticles. No ChEMBL record returned for 5-HMF under either name form. The active 5-HMF has nevertheless reached human trials as Aes-103 (Baxalta/Shire, an allosteric haemoglobin modifier for sickle cell disease); those trials are recorded below as ACTIVE-AGENT-level evidence and are FLAGGED, since the indication and formulation are entirely different from the wound-dressing hydrogel.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Sickle Cell Disease
Enrolment: 35 · Results not recorded
Hypoxia
Enrolment: 12 · Results not recorded
Sickle Cell Disease
Enrolment: 19 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Cutaneous wound healing model in vivo, with in vitro studies in human skin fibroblasts
5-HMF promoted proliferation, migration and collagen production in human skin fibroblasts in vitro. The 5-HMF-loaded PVA/sodium alginate hydrogel gave sustained release and accelerated wound healing in vivo with reduced inflammation, greater angiogenesis, more collagen and improved re-epithelialisa…
Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.